LP 2307: Began an 18-patient Phase I/II trial

LIDAK Pharmaceuticals Inc. (LDAKA), La Jolla, Calif. Product: LP 2307, Large Multivalent Immunogen consisting of melanoma antigens attached to microspheres Indication: Late-stage malignant melanoma S...